

PRODUCT INFORMATION




JNJ-17203212

Item No. 30930

CAS Registry No.: 821768-06-3
Formal Name: 4-[3-(trifluoromethyl)-2-pyridinyl]-
N-[5-(trifluoromethyl)-2-pyridinyl]-
1-piperazinecarboxamide

MF: C₁₇H₁₅F₆N₅O
FW: 419.3
Purity: ≥98%
UV/Vis.: λ_{max}: 249 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JNJ-17203212 is supplied as a crystalline solid. A stock solution may be made by dissolving the JNJ-17203212 in the solvent of choice, which should be purged with an inert gas. JNJ-17203212 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of JNJ-17203212 in these solvents is approximately 30 mg/ml.

Description

JNJ-17203212 is a transient receptor potential vanilloid 1 (TRPV1) antagonist ($K_i = 72$ nM for the recombinant guinea pig channel).¹ It inhibits guinea pig TRPV1 channel activation induced by capsaicin (Item Nos. 92350 | 10010743) or pH decrease (IC_{50} s = 58 and 470 nM, respectively). JNJ-17203212 (20 mg/kg) reduces the number of citric acid- or capsaicin-induced coughs in guinea pigs. It reduces spontaneous and palpitation-induced flinching and guarding in a mouse model of bone cancer pain when administered at a dose of 30 mg/kg.² JNJ-17203212 decreases capsaicin-induced production of calcitonin gene-related peptide (CGRP) in a dose-dependent manner and inflammatory soup-induced trigeminal expression of *cfos* in rat models of migraine.³

References

1. Bhattacharya, A., Scott, B.P., Nasser, N., *et al.* Pharmacology and antitussive efficacy of 4-(3-trifluoromethylpyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. *J. Pharmacol. Exp. Ther.* **323**(2), 665-674 (2007).
2. Ghilardi, J.R., Röhrich, H., Lindsay, T.H., *et al.* Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. *J. Neurosci.* **25**(12), 3126-3131 (2005).
3. Meents, J.E., Hoffmann, J., Chaplan, S.R., *et al.* Two TRPV1 receptor antagonists are effective in two different experimental models of migraine. *J. Headache Pain* **16**, 57 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM